Hvilken er prisen på TMS Co., Ltd. (4891)

Prisen på TMS Co., Ltd. (4891) er $0.73072946

Hva er markedsverdien på TMS Co., Ltd. (4891)

Markedsverdien på TMS Co., Ltd. (4891) er $33.30M

TMS Co., Ltd. (4891) Prishistorikk

Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The company's pipeline includes TMS-007, an SMTP congener demonstrating both prothrombolytic and anti-inflammatory/antioxidative activities, which has advanced through Phase 2a clinical trials for the treatment of acute ischemic stroke. Additionally, TMS-008, another SMTP congener with anti-inflammatory/antioxidative properties, is undergoing nonclinical development for addressing inflammatory complications like acute kidney injury and cancer cachexia. A third product candidate, TMS-009, is currently in preclinical development. TMS Co., Ltd. collaborates with Hokkaido University and Kanazawa University to assess the potential of its drug candidates, has a joint research agreement with Teikyo University to identify renal function biomarkers, and maintains a strategic alliance with Ji Xing Pharmaceuticals Limited.

År	Ytelse
2026 (TTM)	5.13%
2025	-38.86%
2024	2.28%
2023	-76.40%
2022	0.00%

År

Ytelse

2026 (TTM)

5.13%

2025

-38.86%

2024

2.28%

2023

-76.40%

2022

0.00%

Selskap	Aksjepris	Endring 1år%	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$552.07	39.99%	US
Moderna, Inc. MRNA.US	$168.77	527.63%	US
Argenx SE ARGX.US	$1.03K	56.22%	NL
CSL Limited CSL.AX	$120.74	-14.98%	AU
Lonza Group AG LONN.SW	$757.19	6.39%	CH

Selskap

Aksjepris

Endring 1år%

Land